company background image
TOI

Oncology Institute NasdaqCM:TOI Stock Report

Last Price

US$6.51

Market Cap

US$469.6m

7D

-1.5%

1Y

-34.5%

Updated

12 Aug, 2022

Data

Company Financials
TOI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

TOI Stock Overview

The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States.

Oncology Institute Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oncology Institute
Historical stock prices
Current Share PriceUS$6.51
52 Week HighUS$12.66
52 Week LowUS$3.75
Beta1.78
1 Month Change21.00%
3 Month Change6.37%
1 Year Change-34.51%
3 Year Changen/a
5 Year Changen/a
Change since IPO-32.89%

Recent News & Updates

Shareholder Returns

TOIUS HealthcareUS Market
7D-1.5%1.0%1.3%
1Y-34.5%15.6%-11.7%

Return vs Industry: TOI underperformed the US Healthcare industry which returned 15.6% over the past year.

Return vs Market: TOI underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is TOI's price volatile compared to industry and market?
TOI volatility
TOI Average Weekly Movement13.0%
Healthcare Industry Average Movement8.9%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: TOI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: TOI's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2007658Brad Hivelyhttps://theoncologyinstitute.com

The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services.

Oncology Institute Fundamentals Summary

How do Oncology Institute's earnings and revenue compare to its market cap?
TOI fundamental statistics
Market CapUS$469.63m
Earnings (TTM)-US$1.89m
Revenue (TTM)US$220.66m

2.1x

P/S Ratio

-248.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TOI income statement (TTM)
RevenueUS$220.66m
Cost of RevenueUS$177.44m
Gross ProfitUS$43.22m
Other ExpensesUS$45.11m
Earnings-US$1.89m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.026
Gross Margin19.59%
Net Profit Margin-0.86%
Debt/Equity Ratio0%

How did TOI perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is TOI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TOI?

Other financial metrics that can be useful for relative valuation.

TOI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.9x
Enterprise Value/EBITDA-5.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does TOI's PS Ratio compare to its peers?

TOI PS Ratio vs Peers
The above table shows the PS ratio for TOI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.6x
PNTG Pennant Group
1.1x7.3%US$516.3m
HNGR Hanger
0.6x4.7%US$727.3m
JYNT Joint
3.6x17.7%US$325.8m
NHC National HealthCare
1xn/aUS$1.1b
TOI Oncology Institute
2.1xn/aUS$469.6m

Price-To-Sales vs Peers: TOI is expensive based on its Price-To-Sales Ratio (2.1x) compared to the peer average (1.6x).


Price to Earnings Ratio vs Industry

How does TOI's PE Ratio compare vs other companies in the US Healthcare Industry?

Price-To-Sales vs Industry: TOI is expensive based on its Price-To-Sales Ratio (2.1x) compared to the US Healthcare industry average (1.5x)


Price to Sales Ratio vs Fair Ratio

What is TOI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TOI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TOI's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of TOI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TOI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TOI's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Oncology Institute forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


13.0%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oncology Institute has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Oncology Institute's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has Oncology Institute performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


7.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TOI is currently unprofitable.

Growing Profit Margin: TOI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TOI is unprofitable, but has reduced losses over the past 5 years at a rate of 7.8% per year.

Accelerating Growth: Unable to compare TOI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TOI is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (8.1%).


Return on Equity

High ROE: TOI has a negative Return on Equity (0.56%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Oncology Institute's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: TOI's short term assets ($112.2M) exceed its short term liabilities ($36.1M).

Long Term Liabilities: TOI's short term assets ($112.2M) exceed its long term liabilities ($29.6M).


Debt to Equity History and Analysis

Debt Level: TOI is debt free.

Reducing Debt: TOI had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TOI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TOI is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Dividend

What is Oncology Institute current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate TOI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TOI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TOI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TOI's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TOI has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.6yrs

Average management tenure


CEO

Brad Hively

0.75

Tenure

US$11,635,535

Compensation

Mr. Bradford D. Hively, also known as Brad, serves as Strategic Advisors at Riordan, Lewis & Haden. Mr. Hively previously served as an Operating Professional at the firm. He serves as Chief Executive Offic...


CEO Compensation Analysis

Compensation vs Market: Brad's total compensation ($USD11.64M) is above average for companies of similar size in the US market ($USD2.57M).

Compensation vs Earnings: Brad's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: TOI's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: TOI's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 150.9%.


Top Shareholders

Company Information

The Oncology Institute, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: The Oncology Institute, Inc.
  • Ticker: TOI
  • Exchange: NasdaqCM
  • Founded: 2007
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Implied Market Cap: US$469.634m
  • Shares outstanding: 72.14m
  • Website: https://theoncologyinstitute.com

Number of Employees


Location

  • The Oncology Institute, Inc.
  • 18000 Studebaker Road
  • Suite 800
  • Cerritos
  • California
  • 90703
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/12 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.